Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Review

  • Review
    DNAzyme technology and cancer therapy: cleave and let die
    Crispin R. Dass, Peter F.M. Choong and Levon M. Khachigian
    Mol Cancer Ther February 1 2008 7 (2) 243-251; DOI:10.1158/1535-7163.MCT-07-0510

Research Articles: Therapeutics, Targets, and Development

  • Research Articles: Therapeutics, Targets, and Development
    Defective p53 signaling in p53 wild-type tumors attenuates p21waf1 induction and cyclin B repression rendering them sensitive to Chk1 inhibitors that abrogate DNA damage-induced S and G2 arrest
    Aime A. Levesque, Andrew A. Fanous, Alissa Poh and Alan Eastman
    Mol Cancer Ther February 1 2008 7 (2) 252-262; DOI:10.1158/1535-7163.MCT-07-2066

  • Research Articles: Therapeutics, Targets, and Development
    A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction
    Hailan Liu, Yang Liu and Jian-Ting Zhang
    Mol Cancer Ther February 1 2008 7 (2) 263-270; DOI:10.1158/1535-7163.MCT-07-0445

  • Research Articles: Therapeutics, Targets, and Development
    The role of TRPV6 in breast carcinogenesis
    Katrin A. Bolanz, Matthias A. Hediger and Christopher P. Landowski
    Mol Cancer Ther February 1 2008 7 (2) 271-279; DOI:10.1158/1535-7163.MCT-07-0478

  • Research Articles: Therapeutics, Targets, and Development
    Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers
    Jianbo Wang, Ryan Day, Yiyu Dong, Steven J. Weintraub and Loren Michel
    Mol Cancer Ther February 1 2008 7 (2) 280-285; DOI:10.1158/1535-7163.MCT-07-2003

  • Research Articles: Therapeutics, Targets, and Development
    Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer
    Min Li, Uddalak Bharadwaj, Rongxin Zhang, Sheng Zhang, Hong Mu, William E. Fisher, F. Charles Brunicardi, Changyi Chen and Qizhi Yao
    Mol Cancer Ther February 1 2008 7 (2) 286-296; DOI:10.1158/1535-7163.MCT-07-0483

  • Research Articles: Therapeutics, Targets, and Development
    Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells
    Adly Yacoub, Margaret A. Park, Pankaj Gupta, Mohammed Rahmani, Guo Zhang, Hossein Hamed, David Hanna, Devanand Sarkar, Irina V. Lebedeva, Luni Emdad, Moira Sauane, Nicollaq Vozhilla, Sarah Spiegel, Costas Koumenis, Martin Graf, David T. Curiel, Steven Grant, Paul B. Fisher and Paul Dent
    Mol Cancer Ther February 1 2008 7 (2) 297-313; DOI:10.1158/1535-7163.MCT-07-2166

  • Research Articles: Therapeutics, Targets, and Development
    Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling
    Adly Yacoub, Pankaj Gupta, Margaret A. Park, Mohammed Rhamani, Hossein Hamed, David Hanna, Guo Zhang, Devanand Sarkar, Irina V. Lebedeva, Luni Emdad, Costas Koumenis, David T. Curiel, Steven Grant, Paul B. Fisher and Paul Dent
    Mol Cancer Ther February 1 2008 7 (2) 314-329; DOI:10.1158/1535-7163.MCT-07-2150

  • Research Articles: Therapeutics, Targets, and Development
    A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells
    Andreas Vogt, Peter R. McDonald, Aletheia Tamewitz, Rachel P. Sikorski, Peter Wipf, John J. Skoko III and John S. Lazo
    Mol Cancer Ther February 1 2008 7 (2) 330-340; DOI:10.1158/1535-7163.MCT-07-2165

  • Research Articles: Therapeutics, Targets, and Development
    Induction of growth arrest and apoptosis in human breast cancer cells by 3,3-diindolylmethane is associated with induction and nuclear localization of p27kip
    Zhiwei Wang, Bennett W. Yu, KM Wahidur Rahman, Fakhara Ahmad and Fazlul H. Sarkar
    Mol Cancer Ther February 1 2008 7 (2) 341-349; DOI:10.1158/1535-7163.MCT-07-0476

  • Research Articles: Therapeutics, Targets, and Development
    CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo
    Shih-Wei Wang, Shiow-Lin Pan, Yu-Chun Huang, Jih-Hwa Guh, Po-Cheng Chiang, Der-Yi Huang, Sheng-Chu Kuo, Kuo-Hsiung Lee and Che-Ming Teng
    Mol Cancer Ther February 1 2008 7 (2) 350-360; DOI:10.1158/1535-7163.MCT-07-2000

  • Research Articles: Therapeutics, Targets, and Development
    Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines
    Andrea Cavazzoni, Roberta R. Alfieri, Caterina Carmi, Valentina Zuliani, Maricla Galetti, Claudia Fumarola, Raffaele Frazzi, Mara Bonelli, Fabrizio Bordi, Alessio Lodola, Marco Mor and Pier Giorgio Petronini
    Mol Cancer Ther February 1 2008 7 (2) 361-370; DOI:10.1158/1535-7163.MCT-07-0477

  • Research Articles: Therapeutics, Targets, and Development
    6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1–mediated MDR in small cell lung cancer
    Giuseppe Filomeni, Paola Turella, Maria Luisa Dupuis, Olindo Forini, Maria Rosa Ciriolo, Maurizio Cianfriglia, Silvia Pezzola, Giorgio Federici and Anna Maria Caccuri
    Mol Cancer Ther February 1 2008 7 (2) 371-379; DOI:10.1158/1535-7163.MCT-07-0487

  • Research Articles: Therapeutics, Targets, and Development
    Calcitrol (1α,25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells
    Jenny Kaeding, Julie Bélanger, Patrick Caron, Mélanie Verreault, Alain Bélanger and Olivier Barbier
    Mol Cancer Ther February 1 2008 7 (2) 380-390; DOI:10.1158/1535-7163.MCT-07-0455

  • Research Articles: Therapeutics, Targets, and Development
    IκB kinase β inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells
    Elizabeth A. Duncan, Christine A. Goetz, Sarah J. Stein, Katie J. Mayo, Brian J. Skaggs, Karl Ziegelbauer, Charles L. Sawyers and Albert S. Baldwin
    Mol Cancer Ther February 1 2008 7 (2) 391-397; DOI:10.1158/1535-7163.MCT-07-0305

  • Research Articles: Therapeutics, Targets, and Development
    Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells
    Florence Huguet, Nicole Giocanti, Christophe Hennequin, Martine Croisy, Emmanuel Touboul and Vincent Favaudon
    Mol Cancer Ther February 1 2008 7 (2) 398-406; DOI:10.1158/1535-7163.MCT-07-2023

  • Research Articles: Therapeutics, Targets, and Development
    Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
    Shining Wang, Ping Guo, Xiaomin Wang, Qingyu Zhou and James M. Gallo
    Mol Cancer Ther February 1 2008 7 (2) 407-417; DOI:10.1158/1535-7163.MCT-07-2070

  • Research Articles: Therapeutics, Targets, and Development
    Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium
    Paul Beaudry, Monique Nilsson, Matthew Rioth, Daniela Prox, David Poon, Lanwei Xu, Patrick Zweidler-Mckay, Anderson Ryan, Judah Folkman, Sandra Ryeom and John Heymach
    Mol Cancer Ther February 1 2008 7 (2) 418-424; DOI:10.1158/1535-7163.MCT-07-0568

  • Research Articles: Therapeutics, Targets, and Development
    Adrenocortical carcinoma survival rates correlated to genomic copy number variants
    Elizabeth A. Stephan, Tae-Hoon Chung, Clive S. Grant, Seungchan Kim, Daniel D. Von Hoff, Jeffrey M. Trent and Michael J. Demeure
    Mol Cancer Ther February 1 2008 7 (2) 425-431; DOI:10.1158/1535-7163.MCT-07-0267

  • Research Articles: Therapeutics, Targets, and Development
    In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin
    Li Peng, Ruiwu Liu, Mirela Andrei, Wenwu Xiao and Kit S. Lam
    Mol Cancer Ther February 1 2008 7 (2) 432-437; DOI:10.1158/1535-7163.MCT-07-0575

Back to top
PreviousNext
Molecular Cancer Therapeutics: 7 (2)
February 2008
Volume 7, Issue 2
  • Table of Contents
  • About the Cover

Sign up for alerts

Issue Highlights

  • In vivo optical imaging of human lymphoma xenograft using a library-derived peptidomimetic against α4β1 integrin

Jump to

  • Review
  • Research Articles: Therapeutics, Targets, and Development
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement